Navigation Links
Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution
Date:12/3/2009

DOYLESTOWN, Pa., Dec. 3 /PRNewswire-FirstCall/ -- Ted Karkus, Chairman and CEO of The Quigley Corporation, (Nasdaq: QGLY) www.quigleyco.com announced today that the Company has completed its evaluation of its opportunities to develop prescription pharmaceutical and OTC products and has concluded that it is in its best interests to focus primarily on the OTC/Personal Care marketplace, which may include but are not limited to its Cold-EEZE® and Kids-EEZE® brands, as well as other homeopathic, dietary supplement, cosmetic, cosmeceutical, first aid, functional food and beverage products. Mr. Karkus, the Company's Board of Directors, the Company's executive team, and an outside consultant have concluded that the costs and risks associated with continuing to develop a line of prescription pharmaceutical products are not warranted.

Mr. Karkus stated, "The Company has determined that further material investment in the Pharma subsidiary's existing products under development would be curtailed in light of its view concerning market opportunities, regulatory pathways, the need for further robust and consistent preclinical and clinical testing and continued requirements in the areas of commercial formulation and development."

However, the Company has identified certain Pharma subsidiary products that it feels may warrant further reasonable investment in order to determine whether they present significant commercial opportunities. The products it will continue to investigate include QR333 (potential topical symptomatic relief of diabetic peripheral neuropathy); QR440 (potential relief of inflammation and joint pain); and QR448 (potential anti-infective against infectious bronchitis in poultry).

Mr. Karkus has announced that future investment of Company resources in the Quigley Pharma Division will be significantly reduced in favor of continued development and building of the Cold-EEZE® brand and a broader consumer product platform. "We are particularly interested in leveraging our distribution network in mass, pharmacy and grocery retail by acquiring or developing additional personal care and OTC products. Focusing on products that can quickly be brought to market and do not require years of research and development should significantly reduce product development costs and lead time, while at the same time yielding increased revenues and profits," said Mr. Karkus. He added "We are aggressively searching for product acquisitions and researching line extensions of our Cold-EEZE® and Kids-EEZE® brands to accomplish these goals, diversity our product offerings and to set the stage for future growth of our Company."

About The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY) (http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the Cold-EEZE® family of lozenges and sugar free tablets clinically proven to significantly reduce the severity and duration of the common cold. Cold-EEZE® customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has several wholly owned subsidiaries including Quigley Manufacturing Inc., which consists of an FDA approved facility to manufacture Cold-EEZE® lozenges and fulfill other contract manufacturing opportunities, and Quigley Pharma, Inc., (http://www.QuigleyPharma.com), which conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.


CONTACT:
Ted Karkus                     Carl Hymans
Chairman of the Board, CEO     G.S. Schwartz & Co.
(215) 345-0919 ext. 114        (212) 725-4500 ext. 304
                               carlh@schwartz.com

SOURCE Quigley Corporation


'/>"/>
SOURCE Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. The Quigley Corporation Licenses Naturally Derived Compound For Scar Improvement; License Requires Payments Totaling $1.1 Million To The Quigley Corporation Over A Five Year Period For Exclusive Ownership
2. Quigley Anti-Viral Compound QR448(a) Successfully Prevents Transmission of Infectious Bronchitis in Chickens
3. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
4. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
5. Stryker Announces $750 Million Share Repurchase Program and Declares a $0.15 Per Share Quarterly Dividend
6. Upsher-Smith Announces Milestone in Development of CNS Strategy
7. Instacare Moves to Secure Patents for Its Newest Technologies, Announces Parallel Strategies for Its Revolutionary MD@Hand Cell-Centric Products
8. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
9. Varian, Inc. Announces Form 10-K Filing
10. Jupiter Medical Center Announces New High-Definition MRI System
11. TeamHealth Teleradiology Announces New Contracts in South Carolina and Illinois
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... , January 13, 2017 On ... Jones Industrial Average, and the S&P 500 edged lower ... ended Thursday,s trading session in bearish territories. Taking into ... Services equities this morning: Myriad Genetics Inc. (NASDAQ: ... ), INC Research Holdings Inc. (NASDAQ: INCR ...
(Date:1/13/2017)... NEW YORK , Jan. 12, 2017 /PRNewswire-USNewswire/ ... type 1 diabetes (T1D) research, is pleased to ... advocacy efforts, the Centers for Medicare & Medicaid ... devices approved by the FDA for use in ... a significant step toward making them eligible for ...
(Date:1/13/2017)... YORK , Jan. 12, 2017  Rosen Law ... filing of a class action lawsuit on behalf of ... ALXN ) from February 10, 2014 through November 9, ... recover damages for Alexion investors under the federal securities ... go to http://rosenlegal.com/cases-991.html or call Phillip ...
Breaking Medicine Technology:
(Date:1/16/2017)... , ... January 16, 2017 , ... ... availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol ... protocols to understand the scope of their EHS regulatory obligations and rapidly collect, ...
(Date:1/16/2017)... ... ... well-aware of the following facts at present:, Flu and cold ... effect on keeping this particularly bad strain of the flu away , In ... , These facts are well-known among the team at Woodard! About halfway ...
(Date:1/16/2017)... Hills, CA (PRWEB) , ... January 16, 2017 ... ... a manuscript in the Aesthetic Surgery Journal , the official journal of ... he conducted on lower eyelid retraction surgery. The procedure is designed to correct ...
(Date:1/16/2017)... ... 16, 2017 , ... One thing common to all types of cancer is ... as well. The money spent screening for and treating cancer in the United States ... for cancer more than in any other country that has an advanced healthcare system, ...
(Date:1/16/2017)... ... January 16, 2017 , ... Vixiar Medical, Inc. ... the medical device company, effective immediately. , “This is perfect timing for Kevin ... strong track record in medical device market development and revenue growth, particularly in ...
Breaking Medicine News(10 mins):